Maximilian Peter Brandt, Olesya Vakhrusheva, Hubert Hackl, Tamas Daher, Katrin Tagscherer, Wilfried Roth, Igor Tsaur, Florian Handle, Andrea Eigentler, Zoran Culig, Christian Thomas, Holger H H Erb, Axel Haferkamp, Eva Jüngel, Martin Puhr
Resistance to anti-androgens and chemotherapy (Cx) limits therapeutic options for patients with hormone-sensitive (mHSPC) and hormone-resistant prostate cancer (mCRPC). In this context, upregulation of the glucocorticoid receptor (GR) has been identified as a potential bypass mechanism in mCRPC, and a combination of docetaxel and mifepristone (Doc + RU-486), an inhibitor of GR, re-sensitized docetaxel-resistant cell models to Cx. This study was designed to elucidate the molecular mechanisms responsible for this phenomenon...
August 19, 2024: American Journal of Pathology